New drug combo targets Hard-to-Treat mutated cancers
NCT ID NCT05887492
Summary
This study is testing a new oral drug called TNG260, given alone and with the immunotherapy pembrolizumab, for people with advanced solid tumors that have a specific genetic change (STK11 mutation). The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. About 126 adults with cancers like non-small cell lung cancer will receive treatment until side effects occur, the cancer worsens, or they choose to stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
Contact
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
Contact
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
NYU Langone Hematology Oncology Associates-Mineola
RECRUITINGMineola, New York, 11501, United States
Contact
-
New York University Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact
-
SCRI at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
Contact
-
START MidWest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
Sarah Cannon Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
UCLA Hematology/Oncology
RECRUITINGSanta Monica, California, 90404, United States
Contact
-
US Oncology Investigational Products Center
RECRUITINGDallas, Texas, 75246, United States
Contact
-
US Oncology Investigational Products Center
RECRUITINGNorfolk, Virginia, 23502, United States
Contact
Conditions
Explore the condition pages connected to this study.